Current Perspectives on the Use of Continuous Subcutaneous Insulin Infusion in the Acute Care Setting and Overview of Therapy

Critical Care Nursing Quarterly

Volumn 27, Issue 2, 2004, Pages 172-184

  Lee, Scott W ^a   Im, Richard ^a   Magbual, Richard ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Critical care; CSII; Diabetes; Hospitalized; Inpatient acute care; Insulin pump

Indexed keywords

INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

BLOOD GLUCOSE MONITORING; CHILD CARE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE CLASSIFICATION; DOSE CALCULATION; DRUG ABSORPTION; EVIDENCE BASED MEDICINE; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INTENSIVE CARE; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 2342636513     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200404000-00009     Document Type: Review

References (88)

1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26:1079-1087.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26:S33-S50.
4. Reynolds LR. Re-emergence of insulin pump therapy in the 1990s. South Med J. 2000;93:1157-1161.
5. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22:1779-1784.
6. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19:324-327.
7. Boord J, Graber A, Christman J, Powers A. Practical management of diabetes in critically ill patients. Am J Respir Crit Care Med. 2001;164:1763-1767.
8. Moss M, Guidot DM, Steinberg KP, et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med. 2000;28:2187-2192.
9. Hirsch IB, Paauw DS, Brunzell J. Inpatient management of adults with diabetes. Diabetes Care. 1995;18:870-878.
10. Levetan CS, Magee MF. Hospital management of diabetes. Endocrinol Metab Clin North Am. 2000;29:745-770.
11. Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978;1:204-207.
12. Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979;300:573-578.
13. Pickup JC, Keen H, Viberti GC, et al. Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus. Diabetes Care. 1980;3:290-300.
14. Mecklenburg RS, Benson JW Jr, Becker NM, et al. Clinical use of the insulin infusion pump in 100 patients with type I diabetes. N Engl J Med. 1982; 307:513-518.
15. Hague C. Insulin pumps: evolution of an industry. Reprinted in part with corrections from Diabetes Interview, "Up and Pumping." July 2000.
16. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002;111:69-77.
17. Cao M, Lee S. A cross-sectional analysis of different basal rate requirements for individuals on CSII. Diabetes. 2002;51(suppl 2):A467.
18. Binder C, Lauritzen T, Faber O, et al. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
19. Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics [glucose lowering effect] of HOE901 compared to NPH and ultralente human insulins using the euglycemic clamp technique. Diabetologica. 1999;42(suppl 1):882.
20. Bode BW, Sabbah HT, Gross TM, et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18(suppl 1):S14-S20.
21. Lee S, Cao M, Sajid S, et al. The dual wave bolus feature in CSII controls prolonged post-prandial hyperglycemia better than standard bolus in type 1 diabetes. Diabetes. 2003;52(suppl 1):A438.
22. Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabetes Med. 2002;19:317-321.
23. Wainstein J, Metzger M, Menuchin O, et al. Insulin pump therapy versus multiple daily injections in obese type 2 diabetic patients. Diabetologica. 2001;44(suppl 1):94.
24. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002;25:2074-2080.
25. American Association of Diabetes Educators. AADE position statement: education for continuous subcutaneous insulin infusion pump users. Diabetes Educ. 1997;23:397-398.
26. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med. 2001;161:2293-2300.
27. Wredling R, Lins PE, Adamson U. Factors influencing the clinical outcome of continuous subcutaneous insulin infusion in routine practice. Diabetes Res Clin Pract. 1993;19:59-67.
28. Chantelau E, Spraul M, Muhlhauser I, et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologica. 1989;32:421-426.
29. Ronn B, Mathiesen ER, Vang L, et al. Evaluation of insulin pump treatment under routine conditions. Diabetes Res Clin Pract. 1987;3:191-199.
30. Plotnick LP, Clark LM, Brancati FL, et al. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:1142-1146.
31. Saha ME, Huuppone T, Mikael K, et al. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:1005-1010.
32. Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care. 1999;22:1950-1955.
33. Litton J, Rice A, Friedman N, et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr. 2002;141:490-495.
34. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA. 1991;265:731-736.
35. Penney GC, Mair G, Pearson DW. Outcomes of pregnancies in women with type 1 diabetes in Scotland: a national population-based study. Br J Obstet Gynaecol. 2003;110:315-318.
36. Kimmerle R, Heinemann L, Delecki A, et al. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type I diabetic women. Diabetes Care. 1992;15:1034-1037.
37. Jensen BM, Kuhl C, Molsted-Pedersen L, et al. Preconceptional treatment with insulin infusion pumps in insulin-dependent diabetic women with particular reference to prevention of congenital malformations. Acta Endocrinol Suppl (Copenh). 1986;277:81-85.
38. Potter JM, Reckless JP, Cullen DR. The effect of continuous subcutaneous insulin infusion and conventional insulin regimes on 24-hour variations of blood glucose and intermediary metabolites in the third trimester of diabetic pregnancy. Diabetologica. 1981;21:534-539.
39. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabet Metab. 1986;12:121-129.
40. Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract. 1995;27:199-204.
41. Marcus AO, Fernandez MP. Insulin pump therapy. Acceptable alternative to injection therapy. Postgrad Med. 1996;95:125-132.
42. van den Hove J, Jacobs MC, Tennstedt D, et al. Allergic contact dermatitis from acrylates in insulin pump infusion sets. Contact Dermat. 1996;35:108.
43. Corazza M, Maranini C, Aleotti A, et al. Nickel contact dermatitis due to the needle of an infusion pump, confirmed by microanalysis. Contact Dermat. 1998;39:144.
44. Golden SH, Peart-Vigilance C, Kao WH, et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care. 1999;22:1408-1414.
45. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;55:773-778.
46. Yudkin JS, Oswald GA. Hyperglycemia, diabetes and myocardial infarction. Diabetes Med. 1987;4:13-18.
47. Fava S, Aquilna O, Azzopardi J, Agius Muscat H, Fenech FF. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabetes Med. 1996;13:80-83.
48. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose: independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 1999;22:1827-1831.
49. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance of stress hyperglycemia in non-diabetic patients with myocardial infarction. Br Med J. 1986;293:917-922.
50. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycemia an independent predictior of poor outcome after acute stroke? Results from a long term follow up study. Br Med J. 1997;314:1303-1306.
51. Umpierrez G, Isaacs S, Bazargan N, You X, Thaler L, Kitabchi A. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978-982.
52. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997;34:248-253.
53. Gray CS, Taylor R, French JM, et al. The prognostic value of stress hyperglycemia and previously unrecognized diabetes patients in acute stroke. Diabet Med. 1987;4:237-240.
54. Candelise L, Landi G, Orazio EN, Boccardi E. Prognostic significance of hyperglycemia in acute stroke. Arch Neurol. 1985;42:661-663.
55. Matchar DB, Divine GW, Heyman A, Feussner JR. The influence of hyperglycemia on outcome of cerebral infarction. Ann Intern Med. 1992;117:449-456.
56. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol. 1990;47:1174-1177.
57. O'neill PA, Davies I, Fullerton KJ, Bennett D. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke. 1991;22:842-847.
58. Power MJ, Fullerton KJ, Stout RW. Blood glucose and prognosis of acute stroke. Age Ageing. 1988;17:164-170.
59. Mak K, Mah P, Tey B, Sin FL, Chia G. Fasting blood sugar level: a determinant for in-hospital outcome in patients with first myocardial infarction and without glucose intolerance. Ann Acad Med Singapore. 1993;22:291-295.
60. Husband DJ, Alberti KGMM. Stress hyperglycemia during acute myocardial infarction: an indicator of pre-existing diabetes. Lancet. 1983;2:179-181.
61. Woo E, Ma JTC, Robinson JD, Yu YL. Hyperglycemia is a stress response in acute stroke. Stroke. 1988;19:1359-1364.
62. Surwitt RS, Schneider MS, Feinglos MN. Stress and diabetes mellitus. Diabetes Care. 1992;15:1413-1422.
63. Jorgensen HS, Narcayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke. 1994;25:1977-1984.
64. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67:352-360.
65. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the surgical intensive care units. N Engl J Med. 2001;345:1359-1367.
66. Evans TW. Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med. 2001;345:1417-1418.
67. Mittra B. Potassium, glucose, and insulin intreatment of myocardial infarction. Lancet. 1965;2:607-609.
68. Hirsch I. In-patient hyperglycemia-are we ready to treat it yet? [editorial]. J Clin Endocrinol Metab. 2002;87(3):975-977.
69. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Unrecognized diabetes among hospitalized patients. Diabetes Care. 1998;21:246-249.
70. Robertson C. When your patient is on an insulin pump. Advanstar Medical Economics. 1998. Available at: RNweb.com.
71. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care. 2001:24:S11.
72. Graber AL, McDonald T. Newly identified hyperglycemia among hospitalized patients. South Med J. 2000;93:1070-1072.
73. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Unrecognized diabetes among hospitalized patients. Diabetes Care. 1998;21:246-249.
74. Rose BD. Clinical Physiology of Acid-Base and Electolyte Disorders. 4th ed. New York: McGraw-Hill; 1994.
75. Barrett EJ, DeFronzo RA. Diabetic ketoacidosis: diagnosis and treatment. Hosp Pract [Off Ed]. 1984;19(4):89.
76. Rose B. Pathogenesis of diabetic ketoacidosis and nonketotic hyperglycemia. 1996. Available at: UpToDate.com.
77. Rose B. Overview of the diagnosis and treatment of diabetic ketoacidosis and nonketotic hyperglycemia. 2000. Available at: UpToDate.com.
78. Foster DW. From glycogen to ketones-and back. Diabetes. 1984;33:1188.
79. Sacca L, Orofino G, Petrone A, Vigorito C. Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance. J Clin Invest. 1984;73:1683.
80. Pilkis SJ, El-Maghrabi MR, Claus TH. Fructose 2,6-bisphosphate in control of hepatic gluconeogenesis. From metabolites to molecular genetics. Diabetes Care. 1990;13:582.
81. Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE. Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM). Dan Med Bull. 1989;36(2):176-178.
82. Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H. Multiple insulin injections using pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res. 1987;6(3):155-158.
83. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo Study. Br Med J Clin Res Ed. 1986;293(6556):1195-1199.
84. Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Aagenaes O, Monsand R. Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences. J Intern Med. 1990;228(5):457-464.
85. Schiffrin A, Belmonte MM. Comparison between subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study. Diabetes. 1982;31(3):255-264.
86. Bode BW, Steed RD, Davidson PC. Reduction in sever hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19(4):324-327
87. Ziegler D, Dannehl K, Koschinsky T, Toeller M, Gries FA. Comparison of continuous subcutaneous insulin infusion and intensified conventional therapy in the treatment of type 1 diabetes: a two-year randomized study. Diabetes Nutr Metab Clin Exp. 1990;3(3):203-213.
88. Bode BW, Gross TM, Ghegan M, et al. Breaking the age barrier: a comparison of continuous subcutaneous insulin infusion in adolescents and adults. Diabetologica. 1999;42:227.